Haemonetics (HAE) 10-Q 10 Aug 22 2023 Q1 Quarterly report Financial data

DOCUMENT AND ENTITY INFORMATION

DOCUMENT AND ENTITY INFORMATION - shares	3 Months Ended
	Jul. 02, 2022	Aug. 08, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jul. 02, 2022
Document Transition Report	false
Entity File Number	001-14041
Entity Registrant Name	HAEMONETICS CORP
Entity Central Index Key	0000313143
Current Fiscal Year End Date	--04-01
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Incorporation, State or Country Code	MA
Entity Tax Identification Number	04-2882273
Entity Address, Address Line One	125 Summer Street
Entity Address, City or Town	Boston,
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02110
City Area Code	781
Local Phone Number	848-7100
Title of 12(b) Security	Common stock, $.01 par value per share
Trading Symbol	HAE
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		51,316,543

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Jul. 02, 2022	Jul. 03, 2021
Income Statement [Abstract]
Net revenues	$ 261,458	$ 228,528
Cost of goods sold	119,195	120,443
Gross profit	142,263	108,085
Operating expenses:
Research and development	10,902	12,701
Selling, general and administrative	92,227	91,218
Amortization of Intangible Assets	8,367	12,379
Gain on closing of transaction	0	9,603
Total operating expenses	111,496	106,695
Operating income	30,767	1,390
Interest and other expense, net	(5,273)	(4,398)
Income (loss) before provision for income taxes	25,494	(3,008)
Provision for income taxes	5,617	1,446
Net income (loss)	$ 19,877	$ (4,454)
Basic income (loss) per share (in dollars per share)	$ 0.39	$ (0.09)
Diluted income (loss) per share (in dollars per share)	$ 0.38	$ (0.09)
Weighted average shares outstanding
Basic (in shares)	51,224	50,939
Diluted (in shares)	51,683	50,939
Comprehensive income (loss)	$ 13,114	$ (4,007)

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jul. 02, 2022	Apr. 02, 2022
Current assets:
Cash and cash equivalents	$ 214,948	$ 259,496
Accounts receivable, less allowance of $2,495 at July 2, 2022 and $2,475 at April 2, 2022	146,463	159,376
Inventories, net	277,887	293,027
Prepaid expenses and other current assets	48,485	44,132
Total current assets	687,783	756,031
Property, plant and equipment, net	288,321	258,482
Intangible Assets, Net (Excluding Goodwill)	302,710	310,261
Goodwill	466,115	467,287
Deferred tax asset	4,552	4,468
Other long-term assets	71,045	63,205
Total assets	1,820,526	1,859,734
Current liabilities:
Notes payable and current maturities of long-term debt	6,853	214,148
Accounts payable	57,907	58,371
Accrued payroll and related costs	30,422	48,540
Other current liabilities	85,305	121,207
Total current liabilities	180,487	442,266
Long-term debt, net of current maturities	763,141	559,441
Deferred tax liability	32,622	28,727
Other long-term liabilities	73,853	79,876
Total stockholders’ equity
Common stock, $0.01 par value; Authorized — 150,000,000 shares; Issued and outstanding — 51,315,653 shares at July 2, 2022 and 51,124,240 shares at April 2, 2022	513	511
Additional paid-in capital	580,359	572,476
Retained earnings	222,268	202,391
Accumulated other comprehensive loss	(32,717)	(25,954)
Total stockholders’ equity	770,423	749,424
Total liabilities and stockholders’ equity	$ 1,820,526	$ 1,859,734

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($) $ in Thousands	Jul. 02, 2022	Apr. 02, 2022
Statement of Financial Position [Abstract]
Accounts receivable, allowance	$ 2,495	$ 2,475
Intangible assets, amortization	$ 386,235	$ 376,552
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock, shares issued (in shares)	51,315,653	51,124,240
Common stock, shares outstanding (in shares)	51,315,653	51,124,240

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment	Common Stock	Common Stock Cumulative Effect, Period of Adoption, Adjustment	Additional Paid-in Capital	Additional Paid-in Capital Cumulative Effect, Period of Adoption, Adjustment	Retained Earnings	Retained Earnings Cumulative Effect, Period of Adoption, Adjustment	Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Loss Cumulative Effect, Period of Adoption, Adjustment
Balance (in shares) at Apr. 03, 2021			50,869	0
Balance at Apr. 03, 2021	$ 731,670	$ (60,121)	$ 509	$ 0	$ 602,727	$ (61,156)	$ 157,981	$ 1,035	$ (29,547)	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee stock purchase plan (in shares)			39
Employee stock purchase plan	2,210				2,210
Exercise of stock options (in shares)			14
Exercise of stock options	500		$ 0		500
Issuance of restricted stock, net of cancellations (in shares)			91
Issuance of restricted stock, net of cancellations	0		$ 1		(1)		0
Share-based compensation expense	6,828				6,828
Net income (loss)	(4,454)						(4,454)
Other comprehensive income (loss)	447						0		447
Balance (in shares) at Jul. 03, 2021			51,013
Balance at Jul. 03, 2021	677,080		$ 510		551,108		154,562		(29,100)
Balance (in shares) at Apr. 02, 2022			51,124
Balance at Apr. 02, 2022	749,424		$ 511		572,476		202,391		(25,954)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee stock purchase plan (in shares)			57
Employee stock purchase plan	2,459				2,459
Exercise of stock options (in shares)			3
Exercise of stock options	127		$ 1		126
Issuance of restricted stock, net of cancellations (in shares)			131
Issuance of restricted stock, net of cancellations	0		$ 1		(1)
Share-based compensation expense	5,299				5,299
Net income (loss)	19,877						19,877
Other comprehensive income (loss)	(6,763)								(6,763)
Balance (in shares) at Jul. 02, 2022			51,315
Balance at Jul. 02, 2022	$ 770,423		$ 513		$ 580,359		$ 222,268		$ (32,717)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Jul. 02, 2022	Jul. 03, 2021
Cash Flows from Operating Activities:
Net income (loss)	$ 19,877	$ (4,454)
Non-cash items:
Depreciation and amortization	22,447	25,033
Impairment of assets	94	5,144
Share-based compensation expense	5,299	6,828
Amortization of deferred finance costs	797	1,019
Benefit for losses on inventory	(2,075)	(544)
Gain on closing of transaction	0	9,603
Contingent consideration expense	(504)	9,774
Other non-cash operating activities	1,602	4,940
Change in operating assets and liabilities:
Change in accounts receivable	10,358	(5,342)
Change in inventories	15,240	(8,553)
Change in prepaid income taxes	2,118	2,121
Change in other assets and other liabilities	(6,079)	1,256
Change in accounts payable and accrued expenses	(27,181)	(29,299)
Net cash provided by (used in) operating activities	41,993	(1,680)
Cash Flows from Investing Activities:
Capital expenditures	(45,467)	(13,919)
Acquisition	(2,850)	(2,500)
Proceeds from sale of property, plant and equipment	498	568
Other investments	(10,395)	0
Net cash used in investing activities	(58,214)	(15,851)
Cash Flows from Financing Activities:
Repayment of term loan borrowings	(4,375)	(4,375)
Contingent consideration payments	(21,593)	0
Proceeds from employee stock purchase plan	2,459	2,210
Proceeds from exercise of stock options	127	500
Other	(13)	31
Net cash used in financing activities	(23,395)	(1,634)
Effect of exchange rates on cash and cash equivalents	(4,932)	322
Net Change in Cash and Cash Equivalents	(44,548)	(18,843)
Cash and Cash Equivalents at Beginning of Period	259,496	192,305
Cash and Cash Equivalents at End of Period	214,948	173,462
Supplemental Disclosures of Cash Flow Information:
Transfers from inventory to fixed assets for placement of Haemonetics equipment	$ 38,022	$ 3,203

BASIS OF PRESENTATION

BASIS OF PRESENTATION	3 Months Ended
	Jul. 02, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	1. BASIS OF PRESENTATION Basis of Presentation The accompanying unaudited condensed consolidated financial statements of Haemonetics Corporation (“Haemonetics” or the “Company”) presented herein have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of the Company’s management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. All intercompany transactions have been eliminated. Operating results for the three months ended July 2, 2022 are not necessarily indicative of the results that may be expected for the full fiscal year ending April 1, 2023 or any other interim period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes included in the Annual Report on Form 10-K for the fiscal year ended April 2, 2022. The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated as r equired. There were no material recognized or unrecognized subsequent events as of or for the three months ended July 2, 2022, except for those discussed in Note 5, Earnings Per Share and Note 9, Notes Payable and Long-term Debt .

RECENT ACCOUNTING PRONOUNCEMENT

RECENT ACCOUNTING PRONOUNCEMENTS	3 Months Ended
	Jul. 02, 2022
Accounting Standards Update and Change in Accounting Principle [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	2. RECENT ACCOUNTING PRONOUNCEMENTS Standards Implemented In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Codification (“ASC”) Update No. 2019-12 — Income Taxes (Topic 740). The new guidance improves consistent application of and simplifies the accounting for income taxes by removing certain exceptions to the general principals in Topic 740. The Company adopted ASC Update No. 2019-12 effective April 4, 2021. The adoption did not have a material impact on the Company’s financial position or results of operations. In August 2020, the FASB issued ASC Update No. 2020-06 — Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40). The amendments simplify the complexity associated with applying U.S. GAAP for certain financial instruments with characteristics of liabilities and equity. Update No. 2020-06 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The Company early adopted ASC Update No. 2020-06 effective April 4, 2021 using the modified retrospective method, which resulted in a decrease of $61.2 million to additional paid-in capital, a decrease to non-current deferred tax liabilities of $20.0 million, and an increase of $80.3 million to non-current convertible notes, net, on the condensed consolidated balance sheets. Additionally, retained earnings was adjusted to remove amortization expense recognized in prior periods related to the debt discount and the convertible notes no longer have a debt discount that will be amortized, net of taxes. The impact to retained earnings on the condensed consolidated balance sheets as of April 4, 2021 is an increase of $1.0 million. In July 2021, the FASB issued ASC Update No. 2021-05 — Leases (Topic 842). The new guidance requires a lessor to classify a lease with variable lease payments that do not depend on an index or rate as an operating lease at lease commencement if the lease would have been classified as a sales-type lease or a direct financing lease in accordance with the classification criteria of ASC 842 and the lessor would have otherwise recognized a day-one loss. The Company prospectively adopted ASC Update No. 2021-05 effective in the second quarter of fiscal year 2022. The adoption did not have a material impact on the Company’s financial position or results of operations. Standards to be Implemented

RESTRUCTURING

RESTRUCTURING	3 Months Ended
	Jul. 02, 2022
Restructuring and Related Activities [Abstract]
RESTRUCTURING	3. RESTRUCTURING On an ongoing basis, the Company reviews the global economy, the healthcare industry, and the markets in which it competes to identify opportunities for efficiencies, enhance commercial capabilities, align its resources and offer its customers better solutions. In order to realize these opportunities, the Company undertakes restructuring-type activities to transform its business. In July 2019, the Board of Directors of the Company approved the Operational Excellence Program (the “2020 Program”) and delegated authority to the Company’s management to determine the detail of the initiatives that will comprise the program. During fiscal 2022, the Company revised the program to improve product and service quality, reduce cost principally in its manufacturing and supply chain operations and ensure sustainability while helping to offset impacts from a previously announced customer loss, rising inflationary pressures and effects of the COVID-19 pandemic. The Company now expects to incur aggregate charges between $95 million and $105 million by the end of fiscal 2025. The majority of charges will result in cash outlays, including severance and other employee costs, and will be incurred as the specific actions required to execute these initiatives are identified and approved. During the three months ended July 2, 2022 and July 3, 2021, the Company incurred $3.5 million and $9.9 million, respectively, of restructuring and restructuring related costs under this program. Total cumulative charges under this program are $59.2 million . The following table summarizes the activity for restructuring reserves related to the 2020 Program and prior programs for the three months ended July 2, 2022, substantially all of which relates to employee severance and other employee costs: (In thousands) 2020 Program Prior Programs Total Balance at April 2, 2022 $ 2,460 $ 345 $ 2,805 Costs incurred, net of reversals (44) — (44) Payments (703) (20) (723) Balance at July 2, 2022 $ 1,713 $ 325 $ 2,038 The following presents the restructuring costs by line item within our accompanying unaudited Condensed Consolidated Statements of Income and Comprehensive Income: Three Months Ended (In thousands) July 2, July 3, Cost of goods sold $ (206) $ 2,253 Research and development — 105 Selling, general and administrative expenses 162 1,062 $ (44) $ 3,420 As of July 2, 2022, the Company had a restr ucturing liability of $2.0 million , of which $1.7 million is paya ble within the next twelve months. In addition to the restructuring costs included in the table above, the Company also incurred costs that do not constitute restructuring under ASC 420, Exit and Disposal Cost Obligations, and which the Company instead refers to as restructuring related costs. These costs consist primarily of expenditures directly related to the restructuring actions and include program management costs associated with the implementation of outsourcing initiatives and recent accounting standards. The tables below present restructuring and restructuring related costs by reportable segment: Restructuring costs Three Months Ended (In thousands) July 2, 2022 July 3, 2021 Plasma $ (211) $ 2,288 Blood Center — 3 Hospital — (38) Corporate 167 1,167 Total $ (44) $ 3,420 Restructuring related costs Three Months Ended (In thousands) July 2, 2022 July 3, 2021 Plasma $ 640 $ 1,738 Blood Center 2 490 Hospital 89 133 Corporate 2,791 4,274 Total $ 3,522 $ 6,635 Total restructuring and restructuring related costs $ 3,478 $ 10,055

INCOME TAXES

INCOME TAXES	3 Months Ended
	Jul. 02, 2022
Income Tax Disclosure [Abstract]
INCOME TAXES	4. INCOME TAXES The Company conducts business globally and reports its results of operations in a number of foreign jurisdictions in addition to the United States. The Company’s reported tax rate is impacted by the jurisdictional mix of earnings in any given period as the foreign jurisdictions in which it operates have tax rates that differ from the U.S. statutory tax rate. For the three months ended July 2, 2022, the Company reported income tax expense of $5.6 million representing an effective tax rate of 22.0%. The effective tax rate for the three months ended July 2, 2022 includes $0.6 million of discrete tax expense relating to stock compensation shortfalls. For the three months ended July 3, 2021, the Company reported income tax expense of $1.4 million representing an effective tax rate of (48.1)%. The effective tax rate for the three months ended July 3, 2021 includes $0.8 million of discrete tax expense relating to stock compensation shortfalls.

EARNINGS PER SHARE

EARNINGS PER SHARE	3 Months Ended
	Jul. 02, 2022
Earnings Per Share [Abstract]
EARNINGS PER SHARE	5. EARNINGS PER SHARE The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations. Three Months Ended (In thousands, except per share amounts) July 2, July 3, Basic EPS Net income (loss) $ 19,877 $ (4,454) Weighted average shares 51,224 50,939 Basic income (loss) per share $ 0.39 $ (0.09) Diluted EPS Net income (loss) $ 19,877 $ (4,454) Basic weighted average shares 51,224 50,939 Net effect of common stock equivalents 459 — Diluted weighted average shares 51,683 50,939 Diluted income (loss) per share $ 0.38 $ (0.09) Basic earnings per share is calculated using the Company’s weighted-average outstanding common stock. Diluted earnings per share is calculated using its weighted-average outstanding common stock including the dilutive effect of stock awards as determined under the treasury stock method and the convertible senior notes as determined under the net share settlement method. From the time of the issuance of the convertible senior notes, the average market price of the Company's common shares has been less than the initial conversion price, and consequently no shares have been included in diluted earnings per share for the conversion value of the convertible senior notes. For the three months ended July 2, 2022, weighted average shares outstanding, assuming dilution, excludes the impact of 0.9 million anti-dilutive shares. For the three months ended July 3, 2021, the Company recognized a net loss; therefore it excluded the impact of outstanding stock awards from the diluted loss per share calculation as its inclusion would have an anti-dilutive effect. In August 2022, the Company announced that its Board of Directors had authorized the repurchase of up to $300 million of Haemonetics common shares over the next three years. Under the share repurchase program, the Company is authorized to repurchase, from time to time, outstanding shares of common stock in accordance with applicable laws on the open market, including under trading plans established pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in privately negotiated transactions. The actual timing, number and value of shares repurchased will be determined by the Company at its discretion, with the intent of beginning activity under the program during fiscal 2023, and will depend on a number of factors, including market conditions, applicable legal requirements and compliance with the terms of loan covenants. The share repurchase program may be suspended, modified or discontinued at any time, and the Company has no obligation to repurchase any amount of its common stock under the program.

REVENUE

REVENUE	3 Months Ended
	Jul. 02, 2022
Revenue from Contract with Customer [Abstract]
REVENUE	6. REVENUE The Company’s revenue recognition policy is to recognize revenues from product sales, software and services in accordance with ASC Topic 606, Revenue from Contracts with Customers . Revenue is recognized when obligations under the terms of a contract with a customer are satisfied; this occurs with the transfer of control of the Company’s goods or services. The Company considers revenue to be earned when all of the following criteria are met: it has a contract with a customer that creates enforceable rights and obligations; promised products or services are identified; the transaction price, or the consideration it expects to receive for transferring goods or providing services, is determinable and it has transferred control of the promised items to the customer. A promise in a contract to transfer a distinct good or service to the customer is identified as a performance obligation. A contract’s transaction price is allocated to each performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. Some of the Company’s contracts have multiple performance obligations. For contracts with multiple performance obligations, the Company allocates the contract’s transaction price to each performance obligation based on the estimated standalone selling prices of the good or service in the contract. For goods or services for which observable standalone selling prices are not available, the Company uses an expected cost plus a margin approach to estimate the standalone selling price of each performance obligation. As of July 2, 2022, the Company had $24.7 million of its transaction price allocated to remaining performance obligations related to executed contracts with an original duration of one year or more. The Company expects to recognize approximately 76% of this amount as revenue within the next twelve months and the remaining balance thereafter. The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deposits (contract liabilities) on the Condensed Consolidated Balance Sheets. The difference in timing between billing and revenue recognition primarily occurs in software licensing arrangements, resulting in contract assets and contract liabilities. As of July 2, 2022 and April 2, 2022, the Company had contract assets of $6.4 million and $5.5 million, respectively. Contract assets are classified as other current assets and other long-term assets on the Condensed Consolidated Balance Sheets. As of July 2, 2022 and April 2, 2022, the Company had contract liabilities of $25.4 million and $26.8 million, respectively. During the three months ended July 2, 2022, the Company recognized $11.7 million of revenue, respectively, that was included in the above April 2, 2022 contract liability balance.

INVENTORIES

INVENTORIES	3 Months Ended
	Jul. 02, 2022
Inventory Disclosure [Abstract]
INVENTORIES	7. INVENTORIES Inventories are stated at the lower of cost or net realizable value and include the cost of material, labor and manufacturing overhead. Cost is determined with the first-in, first-out method. (In thousands) July 2, April 2, Raw materials $ 92,416 $ 88,886 Work-in-process 18,234 17,187 Finished goods 167,237 186,954 Total inventories $ 277,887 $ 293,027

LEASES

LEASES	3 Months Ended
	Jul. 02, 2022
Leases [Abstract]
LEASES	8. LEASES Lessor Activity Assets on the Company’s balance sheet classified as Haemonetics equipment primarily consist of medical devices installed at customer sites but owned by Haemonetics. These devices are leased to customers under contractual arrangements that typically include an operating or sales-type lease as well as the purchase and consumption of a certain level of disposable products. Sales-type leases are not significant. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where devices are provided under operating lease arrangements, a substantial majority of the entire lease revenue is variable and subject to subsequent non-lease component (disposable products) sales. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Operating lease revenue represents approximately 3 percent of the Company’s total net sales.

NOTES_PAYABLE AND LONG-TERM DEB

NOTES PAYABLE AND LONG-TERM DEBT	3 Months Ended
	Jul. 02, 2022
Debt Disclosure [Abstract]
NOTES PAYABLE AND LONG-TERM DEBT	9. NOTES PAYABLE AND LONG-TERM DEBT Convertible Senior Notes In March 2021, the Company issued $500.0 million aggregate principal amount of 0% convertible senior notes due 2026 (the “2026 Notes”). The 2026 Notes are governed by the terms of the Indenture between the Company and U.S. Bank National Association, as trustee (the “Indenture”). The total net proceeds from the sale of the 2026 Notes, after deducting the initial purchasers’ discounts and debt issuance costs, were approximately $486.7 million. The 2026 Notes will mature on March 1, 2026, unless earlier converted, redeemed or repurchased. During the first quarter of fiscal 2023, the conditions allowing holders of the 2026 Notes to convert have not been met. The 2026 Notes were therefore not convertible as of July 2, 2022 and were classified as long-term debt on the Company’s Condensed Consolidated Balance Sheets. On April 4, 2021, the Company adopted ASC Update No. 2020-06 using the modified retrospective method, which resulted in a decrease of $61.2 million to additional paid-in capital, a decrease to non-current deferred tax liabilities of $20.0 million, and an increase of $80.3 million to non-current convertible notes, net, on the Condensed Consolidated Balance Sheets. Additionally, retained earnings was adjusted to remove amortization expense recognized in prior periods related to the debt discount and the convertible notes no longer have a debt discount that will be amortized, net of taxes. The impact to retained earnings on the Condensed Consolidated Balance Sheets as of April 4, 2021 is an increase of $1.0 million. As of July 2, 2022, the $500.0 million principal balance was netted down by $9.9 million of remaining debt issuance costs, resulting in a net convertible note payable of $490.1 million. Interest expense related to the 2026 Notes was $0.7 million, which is entirely attributable to the amortization of the debt issuance costs. The debt issuance costs are amortized at an effective interest rate of 0.5%. Credit Facilities On June 15, 2018, the Company entered into a credit agreement with certain lenders that provided for a $350.0 million term loan and a $350.0 million revolving loan (together with the term loan, as amended from time to time, the “2018 Credit Facilities”) that mature on June 15, 2023. Interest on the 2018 Credit Facilities is established using LIBOR plus 1.13% - 1.75%, depending on the Company’s leverage ratio. Under the 2018 Credit Facilities, the Company is required to maintain certain leverage and interest coverage ratios specified in the credit agreement as well as other customary non-financial affirmative and negative covenants. At July 2, 2022, $280.0 million was outstanding under the term loan with an effective interest rate of 3.4%. There were no borrowings outstanding on the revolving loan. The Company also has $20.9 million of uncommitted operating lines of credit to fund its global operations under which there were no outstanding borrowings as of July 2, 2022. The Company was in compliance with the leverage and interest coverage ratios specified in the 2018 Credit Facilities as well as all other bank covenants as of July 2, 2022. On July 26, 2022, the Company entered into an amended and restated credit agreement with certain lenders to refinance the 2018 Credit Facilities and extend their maturity date through June 2025. The amended and restated credit agreement provides for a $280 million senior unsecured term loan, the proceeds of which have been used to retire the balance of the term loan under the 2018 Credit Facilities, and a $420 million senior unsecured revolving credit facility (together, the “Revised Credit Facilities”). Loans under the Revised Credit Facilities will initially bear interest at an annual rate equal to the Adjusted Term SOFR Rate (as specified in the amended and restated credit agreement), which is subject to a floor of 0%, plus an applicable rate ranging from 1.125% to 1.750% based on the Company’s consolidated net leverage ratio (as specified in the amended and restated credit agreement) at the applicable measurement date. Adjusted Term SOFR Rate loans are also subject to a credit spread adjustment of 0.10% per annum. The revolving credit facility carries an unused fee that ranges from 0.125% to 0.250% annually based on the Company’s consolidated net leverage ratio at the applicable measurement date. Under the Revised Credit Facilities, the Company is required to maintain certain leverage and interest coverage ratios specified in the amended and restated credit agreement as well as other customary non-financial affirmative and negative covenants. The Revised Credit Facilities mature on June 15, 2025. The principal amount of the term loan under the Revised Credit Facilities is repayable quarterly through the maturity date at a rate of 2.5% for the first year and 5% thereafter, with the unpaid balance due at maturity. As a result of the Company’s entry into the Revised Credit Facilities, the Company has reclassified short term debt to long term on the condensed consolidated balance sheet accordance with ASC 470. The Company has required scheduled principal payments of $5.3 million during the remainder of fiscal 2023.

FINANCIAL INSTRUMENTS AND FAIR

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASURES	3 Months Ended
	Jul. 02, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVES AND FAIR VALUE MEASUREMENTS	10. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS The Company manufactures, markets and sells its products globally. During the three months ended July 2, 2022, 30.4% of the Company’s sales were generated outside the U.S. in local currencies. The Company also incurs certain manufacturing, marketing and selling costs in international markets in local currency. Accordingly, earnings and cash flows are exposed to market risk from changes in foreign currency exchange rates relative to the U.S. Dollar, the Company’s reporting currency. The Company has a program in place that is designed to mitigate the exposure to changes in foreign currency exchange rates. That program includes the use of derivative financial instruments to minimize, for a period of time, the impact on its financial results from changes in foreign exchange rates. The Company utilizes foreign currency forward contracts to hedge the anticipated cash flows from transactions denominated in foreign currencies, primarily the Japanese Yen and the Euro, and to a lesser extent the Swiss Franc, Chinese Yuan and the Mexican Peso. This does not eliminate the impact of the volatility of foreign exchange rates. However, because the Company generally enters into forward contracts one year out, rates are fixed for a one-year period, thereby facilitating financial planning and resource allocation. Designated Foreign Currency Hedge Contracts All of the Company’s designated foreign currency hedge contracts as of July 2, 2022 and April 2, 2022 were cash flow hedges under ASC 815, Derivatives and Hedging (“ASC 815”). The Company records the effective portion of any change in the fair value of designated foreign currency hedge contracts in other comprehensive income until the related third-party transaction occurs. Once the related third-party transaction occurs, the Company reclassifies the effective portion of any related gain or loss on the designated foreign currency hedge contracts to earnings. In the event the hedged forecasted transaction does not occur, or it becomes probable that it will not occur, the Company will reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time. The Company had designated foreign currency hedge contracts outstanding in the contract amount of $49.8 million as of July 2, 2022 and $67.3 million as of April 2, 2022. At July 2, 2022, a gain of $0.9 million, net of tax, will be reclassified to earnings within the next twelve months. Substantially all currency cash flow hedges outstanding as of July 2, 2022 mature within twelve months. Non-Designated Foreign Currency Contracts The Company manages its exposure to changes in foreign currency on a consolidated basis to take advantage of offsetting transactions and balances. It uses foreign currency forward contracts as a part of its strategy to manage exposure related to foreign currency denominated monetary assets and liabilities. These foreign currency forward contracts are entered into for periods consistent with currency transaction exposures, generally one month. They are not designated as cash flow or fair value hedges under ASC 815. These forward contracts are marked-to-market with changes in fair value recorded to earnings. The Company had non-designated foreign currency hedge contracts under ASC 815 outstanding in the contract amount of $44.1 million as of July 2, 2022 and $39.5 million as of April 2, 2022. Interest Rate Swaps On June 15, 2018, the Company entered into the 2018 Credit Facilities, which provided for a $350.0 million term loan and a $350.0 million revolving credit facility. Under the terms of the 2018 Credit Facilities, interest is established using LIBOR plus 1.13% - 1.75%. As a result, the Company’s earnings and cash flows are exposed to interest rate risk from changes to LIBOR. Part of the Company’s interest rate risk management strategy includes the use of interest rate swaps to mitigate its exposure to changes in variable interest rates. The Company’s objective in using interest rate swaps is to add stability to interest expense and to manage and reduce the risk inherent in interest rate fluctuations. In August 2018, the Company entered into two interest rate swap agreements (the “Swaps”) to pay an average fixed rate of 2.80% on a total notional value of $241.9 million of debt. As a result of the Swaps, 70% of the Term Loan previously exposed to interest rate risk from changes in LIBOR is now fixed at a rate of 4.05%. The Swaps mature on June 15, 2023. As of July 2, 2022 , the notional value was $196.0 million. The Company designated the Swaps as cash flow hedges of variable interest rate risk associated with $345.6 million of indebtedness. For the three months ended July 2, 2022, a gain of $3.1 million, net of tax, was recorded in accumulated other comprehensive loss to recognize the effective portion of the fair value of the Swaps that qualify as cash flow hedges. On July 26, 2022, the Company entered into an amended and restated credit agreement to refinance the 2018 Credit Facilities and extend the maturity date to June 15, 2025. The Company is in the process of evaluating additional interest rate swap protection that would extend beyond June 2023. Trade Receivables In the ordinary course of business, the Company grants trade credit to its customers on normal credit terms. In an effort to reduce its credit risk, the Company (i) establishes credit limits for all customers, (ii) performs ongoing credit evaluations of customers’ financial condition, (iii) monitors the payment history and aging of customers’ receivables, and (iv) monitors open orders against an individual customer’s outstanding receivable balance. The Company’s allowance for credit losses is maintained for trade accounts receivable based on the expected collectability, the historical collection experience, the length of time an account is outstanding, the financial position of the customer and information provided by credit rating se rvices. To date, the Company has not experienced significant customer payment defaults, or identified other significant collectability concerns. The following is a rollforward of the allowance for credit losses: Three Months Ended (In thousands) July 2, 2022 July 3, 2021 Beginning balance $ 2,475 $ 2,226 Credit (gain) loss 146 27 Write-offs (126) (17) Ending balance $ 2,495 $ 2,236 Fair Value of Derivative Instruments The following table presents the effect of the Company’s derivative instruments designated as cash flow hedges and those not designated as hedging instruments under ASC 815 in its unaudited Condensed Consolidated Statements of Income and Comprehensive Income for the three months ended July 2, 2022: (In thousands) Amount of Gain Recognized Amount of Gain (Loss) Reclassified Location in Amount of Gain Excluded from Location in Designated foreign currency hedge contracts, net of tax $ 900 $ 1,242 Net revenues, COGS and SG&A $ 101 Interest and other expense, net Non-designated foreign currency hedge contracts $ — $ — $ 925 Interest and other expense, net Designated interest rate swaps, net of tax $ 2,350 $ (799) Interest and other expense, net $ — The Company did not have fair value hedges or net investment hedges outstanding as of July 2, 2022 or April 2, 2022. As of July 2, 2022, no material deferred taxes were recognized for designated foreign currency hedges. ASC 815 requires all derivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. The Company determines the fair value of its derivative instruments using the framework prescribed by ASC 820, Fair Value Measurements and Disclosures , by considering the estimated amount it would receive or pay to sell or transfer these instruments at the reporting date and by taking into account current interest rates, currency exchange rates, current interest rate curves, interest rate volatilities, the creditworthiness of the counterparty for assets, and its creditworthiness for liabilities. In certain instances, the Company may utilize financial models to measure fair value. Generally, it uses inputs that include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; other observable inputs for the asset or liability; and inputs derived principally from, or corroborated by, observable market data by correlation or other means. As of July 2, 2022, the Company has classified its derivative assets and liabilities within Level 2 of the fair value hierarchy prescribed by ASC 815, as discussed below, because these observable inputs are available for substantially the full term of its derivative instruments. The following tables present the fair value of the Company’s derivative instruments as they appear in its Condensed Consolidated Balance Sheets as of July 2, 2022 and April 2, 2022: (In thousands) Location in Condensed Consolidated As of As of July 2, 2022 April 2, 2022 Derivative Assets: Designated foreign currency hedge contracts Other current assets $ 4,528 $ 3,133 Non-designated foreign currency hedge contracts Other current assets 110 99 Designated interest rate swaps Other current assets 49 — $ 4,687 $ 3,232 Derivative Liabilities: Designated foreign currency hedge contracts Other current liabilities $ 282 $ 56 Non-designated foreign currency hedge contracts Other current liabilities 196 25 Designated interest rate swaps Other current liabilities — 1,813 $ 478 $ 1,894 Other Fair Value Measurements Fair value is defined as the exit price that would be received from the sale of an asset or paid to transfer a liability, using assumptions that market participants would use in pricing an asset or liability. The fair value guidance establishes the following three-level hierarchy used for measuring fair value: • Level 1 — Inputs to the valuation methodology are quoted market prices for identical assets or liabilities. • Level 2 — Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs. • Level 3 — Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk. The Company’s money market funds carried at fair value are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. Fair Value Measured on a Recurring Basis Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of July 2, 2022 and April 2, 2022. As of July 2, 2022 (In thousands) Level 1 Level 2 Level 3 Total Assets Money market funds $ 44,030 $ — $ — $ 44,030 Designated foreign currency hedge contracts — 4,528 — 4,528 Non-designated foreign currency hedge contracts — 110 — 110 Designated interest rate swaps — 49 — 49 $ 44,030 $ 4,687 $ — $ 48,717 Liabilities Designated foreign currency hedge contracts $ — $ 282 $ — $ 282 Non-designated foreign currency hedge contracts — 196 — 196 Contingent consideration — — 877 877 $ — $ 478 $ 877 $ 1,355 As of April 2, 2022 Level 1 Level 2 Level 3 Total Assets Money market funds $ 97,425 $ — $ — $ 97,425 Designated foreign currency hedge contracts — 3,133 — 3,133 Non-designated foreign currency hedge contracts — 99 — 99 $ 97,425 $ 3,232 $ — $ 100,657 Liabilities Designated foreign currency hedge contracts $ — $ 56 $ — $ 56 Non-designated foreign currency hedge contracts — 25 — 25 Designated interest rate swaps — 1,813 — 1,813 Contingent consideration — — 33,675 33,675 $ — $ 1,894 $ 33,675 $ 35,569 Foreign currency hedge contracts - The fair value of foreign currency hedge contracts was measured using significant other observable inputs and valued by reference to over-the-counter quoted market prices for similar instruments. The Company does not believe that the fair value of these derivative instruments differs significantly from the amount that could be realized upon settlement or maturity, or that the changes in fair value will have a significant effect on its results of operations, financial condition or cash flows. Interest rate swaps - The fair values of interest rate swaps are measured using the present value of expected future cash flows using market-based observable inputs, including credit risk and interest rate yield curves. The Company does not believe that the fair values of these derivative instruments differ significantly from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a significant effect on its results of operations, financial condition or cash flows. Contingent consideration - The fair value of contingent consideration liabilities is based on significant unobservable inputs, including management estimates and assumptions, and is measured based on the probability-weighted present value of the payments expected to be made. Accordingly, the fair value of contingent consideration has been classified as level 3 within the fair value hierarchy. The recurring level 3 fair value measurements of contingent consideration liabilities include the following significant unobservable inputs: Fair Value at Valuation Unobservable (In thousands) July 2, 2022 Technique Input Range Revenue-based payments $ 877 Discounted cash flow Discount rate 8.5% Projected year of payment 2022 - 2023 The fair value of contingent consideration associated with acquisitions was $0.9 million at July 2, 2022 and was included in other liabilities. A reconciliation of the change in the fair value of contingent consideration is included in the following table: (In thousands) Balance at April 2, 2022 $ 33,675 Change in fair value (504) Payments (32,293) Currency translation (1) Balance at July 2, 2022 $ 877 Other Fair Value Disclosures The Term Loan, which is carried at amortized cost, accounts receivable and accounts payable approximate fa ir value. The fair value of the 2026 Notes as of July 2, 2022 was $396.1 million, which was determined by using the market price on the last trading day of the reporting period.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Jul. 02, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	11. COMMITMENTS AND CONTINGENCIES The Company is a party to various legal proceedings and claims arising out of the ordinary course of its business. The Company believes that, except for those matters described below, there are no other proceedings or claims pending against it the ultimate resolution of which could have a material adverse effect on its financial condition or results of operations. At each reporting period, management evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies, for all matters. Legal costs are expensed as incurred. During the third quarter of fiscal 2021, the Company received a subpoena from the U.S. Attorney’s Office for the District of Massachusetts. The subpoena requests certain documents regarding the Company’s apheresis and autotransfusion devices and disposables, including documents relating to product complaints and adverse event reporting, regulatory clearances and product design changes, among other matters. The Company is fully cooperating with this inquiry.

SEGMENT AND ENTERPRISE-WIDE INF

SEGMENT AND ENTERPRISE-WIDE INFORMATION	3 Months Ended
	Jul. 02, 2022
Segment Reporting [Abstract]
SEGMENT AND ENTERPRISE-WIDE INFORMATION	12. SEGMENT AND ENTERPRISE-WIDE INFORMATION The Company determines its reportable segments by first identifying its operating segments, and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. The Company’s reporting structure aligns with its operating structure of three global business units and the information that is regularly reviewed by the Company’s chief operating decision maker. The Company’s reportable segments are as follows: • Plasma • Blood Center • Hospital Management measures and evaluates the operating segments based on operating income. Management excludes certain corporate expenses from segment operating income. In addition, certain amounts that management considers to be non-recurring or non-operational are excluded from segment operating income because management evaluates the operating results of the segments excluding such items. These items include integration and transaction costs, deal amortization, restructuring and restructuring related costs, impairments, accelerated device depreciation and related costs, costs related to compliance with the European Union Medical Device Regulation (“MDR”) and In Vitro Diagnostic Regulation (“IVDR”), unusual or infrequent and material litigation-related charges and gains and losses on dispositions and sale of assets. Although these amounts are excluded from segment operating income, as applicable, they are included in the reconciliations that follow. Management measures and evaluates the Company’s net revenues and operating income using internally derived standard currency exchange rates that remain constant from year to year; therefore, segment information is presented on this basis. Selected information by reportable segment is presented below: Three Months Ended (In thousands) July 2, July 3, Net revenues Plasma $ 103,042 $ 71,803 Blood Center 66,573 71,736 Hospital 89,184 77,607 Net revenues by business unit 258,799 221,146 Service (1) 5,137 5,268 Effect of exchange rates (2,478) 2,114 Net revenues $ 261,458 $ 228,528 (1) Reflects revenue for service, maintenance and parts Three Months Ended (In thousands) July 2, July 3, Segment operating income Plasma $ 55,126 $ 35,346 Blood Center 30,377 33,882 Hospital 34,722 31,597 Segment operating income 120,225 100,825 Corporate expenses (1) (81,584) (68,731) Effect of exchange rates 6,245 5,812 Integration and transaction costs 758 (16,733) Deal amortization (8,367) (12,379) Restructuring and restructuring related costs (3,478) (10,055) Impairment of assets and PCS2 related charges 350 (3,643) MDR and IVDR costs (3,186) (2,371) Litigation-related charges (196) (938) Gains on divestitures and sale of assets — 9,603 Operating income $ 30,767 $ 1,390 (1) Reflects shared service expenses including quality and regulatory, customer and field service, research and development, manufacturing and supply chain, as well as other corporate support functions. Management reviews revenue based on the reportable segments noted above. Although these reportable segments are primarily product-based, they differ from the Company’s product line revenues for Plasma products and services and Blood Center products and services. Specifically, the Blood Center reportable segment includes plasma products utilized for collection in blood centers primarily for transfusion purposes. Additionally, product line revenues also include service revenues which are excluded from the reportable segments. Net revenues by product line are as follows: Three Months Ended (In thousands) July 2, July 3, Plasma products and services $ 118,352 $ 90,509 Blood Center products and services 52,918 57,747 Hospital products and services 90,188 80,272 Net revenues $ 261,458 $ 228,528 Net revenues generated in the Company’s principle operating regions on a reported basis are as follows: Three Months Ended (In thousands) July 2, July 3, United States $ 181,996 $ 141,028 Japan 13,878 17,221 Europe 40,457 43,335 Asia 24,424 25,952 Other 703 992 Net revenues $ 261,458 $ 228,528

ACCUMULATED OTHER COMPREHENSIVE

ACCUMULATED OTHER COMPREHENSIVE LOSS	3 Months Ended
	Jul. 02, 2022
Stockholders' Equity Note [Abstract]
ACCUMULATED OTHER COMPREHENSIVE LOSS	13. ACCUMULATED OTHER COMPREHENSIVE LOSS The components of Accumulated Other Comprehensive Loss are as follows: (In thousands) Foreign Currency Defined Benefit Plans Net Unrealized Gain/(Loss) on Derivatives Total Balance as of April 2, 2022 $ (27,919) $ 1,619 $ 346 $ (25,954) Other comprehensive income (loss) before reclassifications (1) (9,570) — 3,250 (6,320) Amounts reclassified from Accumulated Other Comprehensive Income (1) — — (443) (443) Net current period other comprehensive income (loss) (9,570) — 2,807 (6,763) Balance as of July 2, 2022 $ (37,489) $ 1,619 $ 3,153 $ (32,717) (1) Presented net of income taxes, the amounts of which are insignificant.

RESTRUCTURING (Tables)

RESTRUCTURING (Tables)	3 Months Ended
	Jul. 02, 2022
Restructuring and Related Activities [Abstract]
Schedule of Restructuring Reserve by Type of Cost	The following table summarizes the activity for restructuring reserves related to the 2020 Program and prior programs for the three months ended July 2, 2022, substantially all of which relates to employee severance and other employee costs: (In thousands) 2020 Program Prior Programs Total Balance at April 2, 2022 $ 2,460 $ 345 $ 2,805 Costs incurred, net of reversals (44) — (44) Payments (703) (20) (723) Balance at July 2, 2022 $ 1,713 $ 325 $ 2,038
Schedule of Restructuring and Related Costs	The following presents the restructuring costs by line item within our accompanying unaudited Condensed Consolidated Statements of Income and Comprehensive Income: Three Months Ended (In thousands) July 2, July 3, Cost of goods sold $ (206) $ 2,253 Research and development — 105 Selling, general and administrative expenses 162 1,062 $ (44) $ 3,420 Restructuring costs Three Months Ended (In thousands) July 2, 2022 July 3, 2021 Plasma $ (211) $ 2,288 Blood Center — 3 Hospital — (38) Corporate 167 1,167 Total $ (44) $ 3,420 Restructuring related costs Three Months Ended (In thousands) July 2, 2022 July 3, 2021 Plasma $ 640 $ 1,738 Blood Center 2 490 Hospital 89 133 Corporate 2,791 4,274 Total $ 3,522 $ 6,635 Total restructuring and restructuring related costs $ 3,478 $ 10,055

EARNINGS PER SHARE (Tables)

EARNINGS PER SHARE (Tables)	3 Months Ended
	Jul. 02, 2022
Earnings Per Share [Abstract]
Schedule of Earnings Per Share Reconciliation	The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations. Three Months Ended (In thousands, except per share amounts) July 2, July 3, Basic EPS Net income (loss) $ 19,877 $ (4,454) Weighted average shares 51,224 50,939 Basic income (loss) per share $ 0.39 $ (0.09) Diluted EPS Net income (loss) $ 19,877 $ (4,454) Basic weighted average shares 51,224 50,939 Net effect of common stock equivalents 459 — Diluted weighted average shares 51,683 50,939 Diluted income (loss) per share $ 0.38 $ (0.09)

INVENTORIES (Tables)

INVENTORIES (Tables)	3 Months Ended
	Jul. 02, 2022
Inventory Disclosure [Abstract]
Schedule of Inventories	(In thousands) July 2, April 2, Raw materials $ 92,416 $ 88,886 Work-in-process 18,234 17,187 Finished goods 167,237 186,954 Total inventories $ 277,887 $ 293,027

FINANCIAL INSTRUMENTS AND FAI_2

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASURES (Tables)	3 Months Ended
	Jul. 02, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments	The following table presents the effect of the Company’s derivative instruments designated as cash flow hedges and those not designated as hedging instruments under ASC 815 in its unaudited Condensed Consolidated Statements of Income and Comprehensive Income for the three months ended July 2, 2022: (In thousands) Amount of Gain Recognized Amount of Gain (Loss) Reclassified Location in Amount of Gain Excluded from Location in Designated foreign currency hedge contracts, net of tax $ 900 $ 1,242 Net revenues, COGS and SG&A $ 101 Interest and other expense, net Non-designated foreign currency hedge contracts $ — $ — $ 925 Interest and other expense, net Designated interest rate swaps, net of tax $ 2,350 $ (799) Interest and other expense, net $ —
Schedule of Fair Value of Derivative Instruments as They Appear in Consolidated Balance Sheets	The following tables present the fair value of the Company’s derivative instruments as they appear in its Condensed Consolidated Balance Sheets as of July 2, 2022 and April 2, 2022: (In thousands) Location in Condensed Consolidated As of As of July 2, 2022 April 2, 2022 Derivative Assets: Designated foreign currency hedge contracts Other current assets $ 4,528 $ 3,133 Non-designated foreign currency hedge contracts Other current assets 110 99 Designated interest rate swaps Other current assets 49 — $ 4,687 $ 3,232 Derivative Liabilities: Designated foreign currency hedge contracts Other current liabilities $ 282 $ 56 Non-designated foreign currency hedge contracts Other current liabilities 196 25 Designated interest rate swaps Other current liabilities — 1,813 $ 478 $ 1,894
Schedule of Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis	Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of July 2, 2022 and April 2, 2022. As of July 2, 2022 (In thousands) Level 1 Level 2 Level 3 Total Assets Money market funds $ 44,030 $ — $ — $ 44,030 Designated foreign currency hedge contracts — 4,528 — 4,528 Non-designated foreign currency hedge contracts — 110 — 110 Designated interest rate swaps — 49 — 49 $ 44,030 $ 4,687 $ — $ 48,717 Liabilities Designated foreign currency hedge contracts $ — $ 282 $ — $ 282 Non-designated foreign currency hedge contracts — 196 — 196 Contingent consideration — — 877 877 $ — $ 478 $ 877 $ 1,355 As of April 2, 2022 Level 1 Level 2 Level 3 Total Assets Money market funds $ 97,425 $ — $ — $ 97,425 Designated foreign currency hedge contracts — 3,133 — 3,133 Non-designated foreign currency hedge contracts — 99 — 99 $ 97,425 $ 3,232 $ — $ 100,657 Liabilities Designated foreign currency hedge contracts $ — $ 56 $ — $ 56 Non-designated foreign currency hedge contracts — 25 — 25 Designated interest rate swaps — 1,813 — 1,813 Contingent consideration — — 33,675 33,675 $ — $ 1,894 $ 33,675 $ 35,569 Fair Value at Valuation Unobservable (In thousands) July 2, 2022 Technique Input Range Revenue-based payments $ 877 Discounted cash flow Discount rate 8.5% Projected year of payment 2022 - 2023 (In thousands) Balance at April 2, 2022 $ 33,675 Change in fair value (504) Payments (32,293) Currency translation (1) Balance at July 2, 2022 $ 877
Accounts Receivable, Allowance for Credit Loss	The following is a rollforward of the allowance for credit losses: Three Months Ended (In thousands) July 2, 2022 July 3, 2021 Beginning balance $ 2,475 $ 2,226 Credit (gain) loss 146 27 Write-offs (126) (17) Ending balance $ 2,495 $ 2,236

SEGMENT AND ENTERPRISE-WIDE I_2

SEGMENT AND ENTERPRISE-WIDE INFORMATION (Tables)	3 Months Ended
	Jul. 02, 2022
Segment Reporting [Abstract]
Selected Information by Business Segment	Selected information by reportable segment is presented below: Three Months Ended (In thousands) July 2, July 3, Net revenues Plasma $ 103,042 $ 71,803 Blood Center 66,573 71,736 Hospital 89,184 77,607 Net revenues by business unit 258,799 221,146 Service (1) 5,137 5,268 Effect of exchange rates (2,478) 2,114 Net revenues $ 261,458 $ 228,528 (1) Reflects revenue for service, maintenance and parts Three Months Ended (In thousands) July 2, July 3, Segment operating income Plasma $ 55,126 $ 35,346 Blood Center 30,377 33,882 Hospital 34,722 31,597 Segment operating income 120,225 100,825 Corporate expenses (1) (81,584) (68,731) Effect of exchange rates 6,245 5,812 Integration and transaction costs 758 (16,733) Deal amortization (8,367) (12,379) Restructuring and restructuring related costs (3,478) (10,055) Impairment of assets and PCS2 related charges 350 (3,643) MDR and IVDR costs (3,186) (2,371) Litigation-related charges (196) (938) Gains on divestitures and sale of assets — 9,603 Operating income $ 30,767 $ 1,390 (1) Reflects shared service expenses including quality and regulatory, customer and field service, research and development, manufacturing and supply chain, as well as other corporate support functions.
Schedule of Revenues by Product Line and Geographic Regions	Management reviews revenue based on the reportable segments noted above. Although these reportable segments are primarily product-based, they differ from the Company’s product line revenues for Plasma products and services and Blood Center products and services. Specifically, the Blood Center reportable segment includes plasma products utilized for collection in blood centers primarily for transfusion purposes. Additionally, product line revenues also include service revenues which are excluded from the reportable segments. Net revenues by product line are as follows: Three Months Ended (In thousands) July 2, July 3, Plasma products and services $ 118,352 $ 90,509 Blood Center products and services 52,918 57,747 Hospital products and services 90,188 80,272 Net revenues $ 261,458 $ 228,528 Net revenues generated in the Company’s principle operating regions on a reported basis are as follows: Three Months Ended (In thousands) July 2, July 3, United States $ 181,996 $ 141,028 Japan 13,878 17,221 Europe 40,457 43,335 Asia 24,424 25,952 Other 703 992 Net revenues $ 261,458 $ 228,528

ACCUMULATED OTHER COMPREHENSI_2

ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)	3 Months Ended
	Jul. 02, 2022
Stockholders' Equity Note [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	The components of Accumulated Other Comprehensive Loss are as follows: (In thousands) Foreign Currency Defined Benefit Plans Net Unrealized Gain/(Loss) on Derivatives Total Balance as of April 2, 2022 $ (27,919) $ 1,619 $ 346 $ (25,954) Other comprehensive income (loss) before reclassifications (1) (9,570) — 3,250 (6,320) Amounts reclassified from Accumulated Other Comprehensive Income (1) — — (443) (443) Net current period other comprehensive income (loss) (9,570) — 2,807 (6,763) Balance as of July 2, 2022 $ (37,489) $ 1,619 $ 3,153 $ (32,717) (1) Presented net of income taxes, the amounts of which are insignificant.

RECENT ACCOUNTING PRONOUNCEME_2

RECENT ACCOUNTING PRONOUNCEMENTS (Narrative) (Details) - USD ($) $ in Thousands	Jul. 02, 2022	Apr. 02, 2022	Jul. 03, 2021	Apr. 03, 2021
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders' Equity Attributable to Parent	$ 770,423	$ 749,424	$ 677,080	$ 731,670
Deferred tax liability	(32,622)	(28,727)
Additional Paid-in Capital
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders' Equity Attributable to Parent	580,359	572,476	551,108	602,727
Retained Earnings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders' Equity Attributable to Parent	$ 222,268	202,391	$ 154,562	$ 157,981
Accounting Standards Update 2020-06
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred tax liability		20,000
Convertible Notes Payable, Noncurrent		80,300
Accounting Standards Update 2020-06 | Additional Paid-in Capital
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders' Equity Attributable to Parent		(61,200)
Accounting Standards Update 2020-06 | Retained Earnings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders' Equity Attributable to Parent		$ 1,000

RESTRUCTURING (Narrative) (Deta

RESTRUCTURING (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended
	Jul. 02, 2022	Jul. 03, 2021	Apr. 02, 2022
Restructuring Cost and Reserve [Line Items]
Restructuring liability	$ 2,038		$ 2,805
Restructuring liability payable in next twelve months	1,700
2020 Program
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Incurred Cost	3,500	$ 9,900
Cumulative costs to date	59,200
Restructuring liability	1,713		$ 2,460
2020 Program | Minimum
Restructuring Cost and Reserve [Line Items]
Expected cost	95,000
2020 Program | Maximum
Restructuring Cost and Reserve [Line Items]
Expected cost	$ 105,000

RESTRUCTURING (Schedule of Rest

RESTRUCTURING (Schedule of Restructuring Reserve by Type of Cost) (Details) - USD ($) $ in Thousands	3 Months Ended
	Jul. 02, 2022	Jul. 03, 2021
Restructuring Reserve [Roll Forward]
Balance at April 2, 2022	$ 2,805
Costs incurred, net of reversals	(44)	$ 3,420
Payments	(723)
Balance at July 2, 2022	2,038
2020 Program
Restructuring Reserve [Roll Forward]
Balance at April 2, 2022	2,460
Costs incurred, net of reversals	(44)
Payments	(703)
Balance at July 2, 2022	1,713
Prior Programs
Restructuring Reserve [Roll Forward]
Balance at April 2, 2022	345
Costs incurred, net of reversals	0
Payments	(20)
Balance at July 2, 2022	$ 325

RESTRUCTURING (Schedule of Re_2

RESTRUCTURING (Schedule of Restructuring and Related Costs) (Details) - USD ($) $ in Thousands	3 Months Ended
	Jul. 02, 2022	Jul. 03, 2021
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ (44)	$ 3,420
Restructuring related costs	3,522	6,635
Total restructuring and restructuring related costs	3,478	10,055
Plasma
Restructuring Cost and Reserve [Line Items]
Restructuring costs	(211)	2,288
Restructuring related costs	640	1,738
Blood Center
Restructuring Cost and Reserve [Line Items]
Restructuring costs	0	3
Restructuring related costs	2	490
Hospital
Restructuring Cost and Reserve [Line Items]
Restructuring costs	0	(38)
Restructuring related costs	89	133
Corporate
Restructuring Cost and Reserve [Line Items]
Restructuring costs	167	1,167
Restructuring related costs	2,791	4,274
Cost of goods sold
Restructuring Cost and Reserve [Line Items]
Restructuring costs	(206)	2,253
Research and development
Restructuring Cost and Reserve [Line Items]
Restructuring costs	0	105
Selling, general and administrative expenses
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 162	$ 1,062

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Thousands	3 Months Ended
	Jul. 02, 2022	Jul. 03, 2021
Income Tax Disclosure [Abstract]
Provision for income taxes	$ 5,617	$ 1,446
Reported tax rate	22%	(48.10%)
Discrete tax benefit (expense)	$ (600)	$ 800

EARNINGS PER SHARE (Schedule of

EARNINGS PER SHARE (Schedule of Earnings Per Share Reconciliation) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Jul. 02, 2022	Jul. 03, 2021
Basic EPS
Net income (loss)	$ 19,877	$ (4,454)
Weighted average shares (in shares)	51,224	50,939
Basic income (loss) per share (in dollars per share)	$ 0.39	$ (0.09)
Diluted EPS
Net income (loss)	$ 19,877	$ (4,454)
Net effect of common stock equivalents (in shares)	459	0
Diluted weighted average shares (in shares)	51,683	50,939
Diluted income (loss) per share (in dollars per share)	$ 0.38	$ (0.09)
Anti-dilutive shares (in shares)	900

EARNINGS PER SHARE (Share Repur

EARNINGS PER SHARE (Share Repurchase Program) (Details) - Subsequent Event - USD ($)	3 Months Ended
	Oct. 01, 2022	Aug. 05, 2022
Class of Stock [Line Items]
Share repurchase plan, authorized amount		$ 300,000,000
Share repurchase program, period in force	3 years

REVENUE (Details)

REVENUE (Details) - USD ($) $ in Millions	3 Months Ended
	Jul. 02, 2022	Apr. 02, 2022
Revenue from Contract with Customer [Abstract]
Performance obligation amount	$ 24.7
Performance obligation percent	76%
Contract assets	$ 6.4	$ 5.5
Contract liabilities	25.4	$ 26.8
Revenue recognized	$ 11.7
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-06-28
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Expected timing of satisfaction	12 months

INVENTORIES (Schedule of Invent

INVENTORIES (Schedule of Inventories) (Details) - USD ($) $ in Thousands	Jul. 02, 2022	Apr. 02, 2022
Inventory Disclosure [Abstract]
Raw materials	$ 92,416	$ 88,886
Work-in-process	18,234	17,187
Finished goods	167,237	186,954
Inventories, net	$ 277,887	$ 293,027

NOTES_PAYABLE AND LONG-TERM D_2

NOTES PAYABLE AND LONG-TERM DEBT (Details) - USD ($)			1 Months Ended	3 Months Ended
	Jul. 26, 2022	Jun. 15, 2018	Mar. 31, 2021	Jul. 02, 2022	Apr. 02, 2022	Jul. 03, 2021	Apr. 03, 2021
Debt Instrument [Line Items]
Stockholders' Equity Attributable to Parent				$ (770,423,000)	$ (749,424,000)	$ (677,080,000)	$ (731,670,000)
Deferred tax liability				(32,622,000)	(28,727,000)
Additional Paid-in Capital
Debt Instrument [Line Items]
Stockholders' Equity Attributable to Parent				(580,359,000)	(572,476,000)	(551,108,000)	(602,727,000)
Retained Earnings
Debt Instrument [Line Items]
Stockholders' Equity Attributable to Parent				(222,268,000)	(202,391,000)	$ (154,562,000)	$ (157,981,000)
Accounting Standards Update 2020-06
Debt Instrument [Line Items]
Deferred tax liability					20,000,000
Convertible Notes Payable, Noncurrent					80,300,000
Accounting Standards Update 2020-06 | Additional Paid-in Capital
Debt Instrument [Line Items]
Stockholders' Equity Attributable to Parent					61,200,000
Accounting Standards Update 2020-06 | Retained Earnings
Debt Instrument [Line Items]
Stockholders' Equity Attributable to Parent					$ (1,000,000)
Convertible Debt
Debt Instrument [Line Items]
Debt outstanding				$ 490,100,000
Effective interest rate				0.50%
Interest Expense, Debt				$ 700,000
Convertible Debt | Convertible Senior Notes Due 2026
Debt Instrument [Line Items]
Face amount of debt			$ 500,000,000	500,000,000
Stated rate (as a percent)			0%
Proceeds from Issuance of Debt			$ 486,700,000
Debt Issuance Costs, Net				9,900,000
Credit Facilities
Debt Instrument [Line Items]
Principal repayments, remainder of the fiscal year				5,300,000
Term Loan
Debt Instrument [Line Items]
Face amount of debt		$ 350,000,000
Debt outstanding				$ 280,000,000
Effective interest rate				3.40%
Revolving Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 350,000,000
Revolving credit facility amount outstanding				$ 0
Revolving Credit Facility | LIBOR | Minimum
Debt Instrument [Line Items]
Interest rate		1.13%
Revolving Credit Facility | LIBOR | Maximum
Debt Instrument [Line Items]
Interest rate		1.75%
Uncommitted Operating Lines of Credit
Debt Instrument [Line Items]
Maximum borrowing capacity				20,900,000
Debt outstanding				$ 0
Uncommitted Operating Lines of Credit | Revised Credit Agreement | Revolving Credit Facility | Subsequent Event
Debt Instrument [Line Items]
Face amount of debt	$ 420,000,000
Uncommitted Operating Lines of Credit | Minimum | Revised Credit Agreement | Revolving Credit Facility | Subsequent Event
Debt Instrument [Line Items]
Revolving credit facility unused fee percentage	0.125%
Uncommitted Operating Lines of Credit | Maximum | Revised Credit Agreement | Revolving Credit Facility | Subsequent Event
Debt Instrument [Line Items]
Revolving credit facility unused fee percentage	0.25%
Unsecured Debt | Revised Credit Agreement | Subsequent Event
Debt Instrument [Line Items]
Face amount of debt	$ 280,000,000
Percent of principal amount due in year one	2.50%
Percent of principal amount due after year one per year until maturity	5%
Unsecured Debt | Minimum | Revised Credit Agreement | Subsequent Event
Debt Instrument [Line Items]
Stated rate (as a percent)	1.125%
Interest rate floor	0%
Unsecured Debt | Maximum | Revised Credit Agreement | Subsequent Event
Debt Instrument [Line Items]
Stated rate (as a percent)	1.75%
Unsecured Debt | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Revised Credit Agreement | Subsequent Event
Debt Instrument [Line Items]
Interest rate	0.10%

FINANCIAL INSTRUMENTS AND FAI_3

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Allowance for credit losses (Details) - USD ($) $ in Thousands	3 Months Ended
	Jul. 02, 2022	Jul. 03, 2021
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Beginning balance	$ 2,475	$ 2,226
Credit (gain) loss	146	27
Write-offs	(126)	(17)
Ending balance	$ 2,495	$ 2,236

FINANCIAL INSTRUMENTS AND FAI_4

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASURES (Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments) (Details) $ in Thousands	3 Months Ended
	Jul. 02, 2022 USD ($)
Designated as Hedging Instrument | Cash Flow Hedging | Net revenues, COGS and SG&A
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain Recognized in Accumulated Other Comprehensive Loss	$ 900
Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Loss into Earnings	1,242
Designated as Hedging Instrument | Cash Flow Hedging | Interest and other expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain Excluded from Effectiveness Testing	101
Designated as Hedging Instrument | Interest Rate Swap
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain Recognized in Accumulated Other Comprehensive Loss	3,100
Amount of Gain Excluded from Effectiveness Testing	0
Designated as Hedging Instrument | Interest Rate Swap | Interest and other expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain Recognized in Accumulated Other Comprehensive Loss	2,350
Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Loss into Earnings	(799)
Not Designated as Hedging Instrument | Foreign Exchange Contract
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain Recognized in Accumulated Other Comprehensive Loss	0
Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Loss into Earnings	0
Not Designated as Hedging Instrument | Foreign Exchange Contract | Interest and other expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain Excluded from Effectiveness Testing	$ 925

FINANCIAL INSTRUMENTS AND FAI_5

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASURES (Schedules of Derivatives) (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Jul. 02, 2022	Apr. 02, 2022
Assets
Money market funds	$ 44,030	$ 97,425
Assets fair value	48,717	100,657
Liabilities
Liabilities fair value	1,355	35,569
Level 1
Assets
Money market funds	44,030	97,425
Assets fair value	44,030	97,425
Liabilities
Liabilities fair value	0	0
Level 2
Assets
Money market funds	0	0
Assets fair value	4,687	3,232
Liabilities
Liabilities fair value	478	1,894
Fair Value, Inputs, Level 3
Liabilities
Liabilities fair value	877	33,675
Designated as Hedging Instrument
Assets
Derivative Assets	4,687	3,232
Liabilities
Derivative Liabilities	478	1,894
Foreign Exchange Contract | Designated as Hedging Instrument
Assets
Derivative Assets	4,528	3,133
Liabilities
Derivative Liabilities	282	56
Foreign Exchange Contract | Designated as Hedging Instrument | Level 1
Assets
Derivative Assets	0	0
Liabilities
Derivative Liabilities	0	0
Foreign Exchange Contract | Designated as Hedging Instrument | Level 2
Assets
Derivative Assets		3,133
Liabilities
Derivative Liabilities		56
Foreign Exchange Contract | Not Designated as Hedging Instrument
Assets
Derivative Assets	110	99
Liabilities
Derivative Liabilities	196	25
Foreign Exchange Contract | Not Designated as Hedging Instrument | Level 1
Assets
Derivative Assets	0	0
Liabilities
Derivative Liabilities	0	0
Foreign Exchange Contract | Not Designated as Hedging Instrument | Level 2
Assets
Derivative Assets		99
Foreign Exchange Contract | Other Current Assets | Designated as Hedging Instrument
Assets
Derivative Assets		3,133
Foreign Exchange Contract | Other Current Assets | Designated as Hedging Instrument | Level 2
Assets
Derivative Assets	4,528
Foreign Exchange Contract | Other Current Assets | Not Designated as Hedging Instrument
Assets
Derivative Assets		99
Foreign Exchange Contract | Other Current Assets | Not Designated as Hedging Instrument | Level 2
Assets
Derivative Assets	110
Foreign Exchange Contract | Other Current Liabilities | Designated as Hedging Instrument
Liabilities
Derivative Liabilities		56
Foreign Exchange Contract | Other Current Liabilities | Designated as Hedging Instrument | Level 2
Liabilities
Derivative Liabilities	282
Foreign Exchange Contract | Other Current Liabilities | Not Designated as Hedging Instrument
Liabilities
Derivative Liabilities		25
Foreign Exchange Contract | Other Current Liabilities | Not Designated as Hedging Instrument | Level 2
Liabilities
Derivative Liabilities	196	25
Interest Rate Swap | Designated as Hedging Instrument
Liabilities
Derivative Liabilities		1,813
Interest Rate Swap | Designated as Hedging Instrument | Level 1
Liabilities
Derivative Liabilities		0
Interest Rate Swap | Designated as Hedging Instrument | Level 2
Liabilities
Derivative Liabilities		1,813
Interest Rate Swap | Other Current Liabilities | Designated as Hedging Instrument
Liabilities
Derivative Liabilities		1,813
Interest Rate Swap | Other Current Liabilities | Designated as Hedging Instrument | Level 2
Liabilities
Derivative Liabilities	0
Contingent Consideration
Liabilities
Liabilities fair value	877	33,675
Contingent Consideration | Revenue Based Payments | Valuation Technique, Discounted Cash Flow
Liabilities
Liabilities fair value	$ 877
Derivative fixed interest rate	8.50%
Contingent Consideration | Fair Value, Inputs, Level 3
Liabilities
Liabilities fair value	$ 877	$ 33,675
Contingent Consideration | Other Current Liabilities
Liabilities
Liabilities fair value	$ 900

FINANCIAL INSTRUMENTS AND FAI_6

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASURES (Narrative) (Details)		3 Months Ended
	Jun. 15, 2018 USD ($)	Jul. 02, 2022 USD ($)	Apr. 02, 2022 USD ($)	Aug. 31, 2018 USD ($) swap
Level 2
Derivative [Line Items]
Convertible notes, fair value		$ 396,100,000
Fair Value, Recurring [Member]
Derivative [Line Items]
Liabilities fair value		1,355,000	$ 35,569,000
Fair Value, Recurring [Member] | Level 2
Derivative [Line Items]
Liabilities fair value		478,000	1,894,000
Term Loan
Derivative [Line Items]
Face amount of debt	$ 350,000,000
Debt outstanding		$ 280,000,000
Revolving Credit Facility
Derivative [Line Items]
Maximum borrowing capacity	$ 350,000,000
Revolving Credit Facility | LIBOR | Minimum
Derivative [Line Items]
Interest rate	1.13%
Revolving Credit Facility | LIBOR | Maximum
Derivative [Line Items]
Interest rate	1.75%
Foreign Exchange Contract
Derivative [Line Items]
Percentage of sales generated outside the US		30.40%
Maturity period for foreign currency contracts		1 year
Contingent Consideration | Fair Value, Recurring [Member]
Derivative [Line Items]
Liabilities fair value		$ 877,000	33,675,000
Contingent Consideration, Acquisition Date Fair Value		(504,000)
Contingent Consideration, Fair Value, Payments		(32,293,000)
Contingent Consideration, Foreign Currency Translation		(1,000)
Contingent Consideration | Fair Value, Recurring [Member] | Other Current Liabilities
Derivative [Line Items]
Liabilities fair value		900,000
Cash Flow Hedging | Interest Rate Swap
Derivative [Line Items]
Number of instruments held | swap				2
Derivative fixed interest rate				2.80%
Notional amount		196,000,000		$ 241,900,000
Cash Flow Hedging | Interest Rate Swap | LIBOR
Derivative [Line Items]
Debt exposed to interest rate risk				70%
Derivative fixed interest rate				4.05%
Designated as Hedging Instrument | Foreign Exchange Contract
Derivative [Line Items]
Deferred income tax expense (benefit)		0
Designated as Hedging Instrument | Foreign Exchange Contract
Derivative [Line Items]
Designated foreign currency hedge contracts outstanding		49,800,000	67,300,000
Designated as Hedging Instrument | Cash Flow Hedging
Derivative [Line Items]
Gain (loss) to be reclassified within the next twelve months		900,000
Designated as Hedging Instrument | Interest Rate Swap
Derivative [Line Items]
Debt outstanding				$ 345,600,000
Amount of Gain Recognized in Accumulated Other Comprehensive Loss		3,100,000
Designated as Hedging Instrument | Interest Rate Swap | Interest and other expense, net
Derivative [Line Items]
Amount of Gain Recognized in Accumulated Other Comprehensive Loss		2,350,000
Not Designated as Hedging Instrument | Foreign Exchange Contract
Derivative [Line Items]
Non-designated foreign currency hedge contracts outstanding		44,100,000	$ 39,500,000
Amount of Gain Recognized in Accumulated Other Comprehensive Loss		$ 0

SEGMENT AND ENTERPRISE-WIDE I_3

SEGMENT AND ENTERPRISE-WIDE INFORMATION (Details) $ in Thousands	3 Months Ended
	Jul. 02, 2022 USD ($) segment	Jul. 03, 2021 USD ($)
Segment Reporting Information [Line Items]
Number of reportable segments | segment	3
Net revenues before foreign exchange impact	$ 258,799	$ 221,146
Effect of exchange rates	(2,478)	2,114
Net revenues	261,458	228,528
Operating (loss) income	30,767	1,390
Effect of exchange rates	6,245	5,812
Amortization	8,367	12,379
Restructuring and turnaround costs	(3,478)	(10,055)
Impairment of assets and PCS2 related charges	350	(3,643)
Integration and transaction costs	758	(16,733)
MDR and IVDR costs	(3,186)	(2,371)
Litigation-related charges	(196)	(938)
Gain on sale of assets	0	9,603
United States
Segment Reporting Information [Line Items]
Net revenues	181,996	141,028
Japan
Segment Reporting Information [Line Items]
Net revenues	13,878	17,221
Europe
Segment Reporting Information [Line Items]
Net revenues	40,457	43,335
Asia
Segment Reporting Information [Line Items]
Net revenues	24,424	25,952
Other
Segment Reporting Information [Line Items]
Net revenues	703	992
Service
Segment Reporting Information [Line Items]
Net revenues before foreign exchange impact	5,137	5,268
Plasma products and services
Segment Reporting Information [Line Items]
Net revenues	118,352	90,509
Blood Center products and services
Segment Reporting Information [Line Items]
Net revenues	52,918	57,747
Hospital products and services
Segment Reporting Information [Line Items]
Net revenues	90,188	80,272
Plasma
Segment Reporting Information [Line Items]
Net revenues before foreign exchange impact	103,042	71,803
Blood Center
Segment Reporting Information [Line Items]
Net revenues before foreign exchange impact	66,573	71,736
Hospital
Segment Reporting Information [Line Items]
Net revenues before foreign exchange impact	89,184	77,607
Operating Segments
Segment Reporting Information [Line Items]
Operating (loss) income	120,225	100,825
Operating Segments | Plasma
Segment Reporting Information [Line Items]
Operating (loss) income	55,126	35,346
Operating Segments | Blood Center
Segment Reporting Information [Line Items]
Operating (loss) income	30,377	33,882
Operating Segments | Hospital
Segment Reporting Information [Line Items]
Operating (loss) income	34,722	31,597
Corporate
Segment Reporting Information [Line Items]
Operating (loss) income	$ 81,584	$ 68,731

ACCUMULATED OTHER COMPREHENSI_3

ACCUMULATED OTHER COMPREHENSIVE LOSS (Details) - USD ($) $ in Thousands	3 Months Ended
	Jul. 02, 2022	Jul. 03, 2021
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance as of April 2, 2022	$ (25,954)
Other comprehensive income (loss) before reclassifications	(6,320)
Amounts reclassified from Accumulated Other Comprehensive Income (Loss)	(443)
Net current period other comprehensive income (loss)	(6,763)	$ 447
Balance as of July 2, 2022	(32,717)
Foreign Currency
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance as of April 2, 2022	(27,919)
Other comprehensive income (loss) before reclassifications	(9,570)
Amounts reclassified from Accumulated Other Comprehensive Income (Loss)	0
Net current period other comprehensive income (loss)	(9,570)
Balance as of July 2, 2022	(37,489)
Defined Benefit Plans
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance as of April 2, 2022	1,619
Other comprehensive income (loss) before reclassifications	0
Amounts reclassified from Accumulated Other Comprehensive Income (Loss)	0
Net current period other comprehensive income (loss)	0
Balance as of July 2, 2022	1,619
Net Unrealized Gain/(Loss) on Derivatives
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance as of April 2, 2022	346
Other comprehensive income (loss) before reclassifications	3,250
Amounts reclassified from Accumulated Other Comprehensive Income (Loss)	(443)
Net current period other comprehensive income (loss)	2,807
Balance as of July 2, 2022	$ 3,153

Uncategorized Items - hae-20220

Label	Element	Value
Accounting Standards Update [Extensible Enumeration]	us-gaap_AccountingStandardsUpdateExtensibleList	Accounting Standards Update 2020-06 [Member]